As filed with the Securities and Exchange Commission on June 1, 2012

Registration No. 333-144665

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO

 

FORM S-3

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

BIOSANTE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

111 Barclay Boulevard

Lincolnshire, Illinois 60069

(847) 478-0500

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Phillip B. Donenberg

Senior Vice President of Finance, Chief Financial Officer and Secretary

BioSante Pharmaceuticals, Inc.

111 Barclay Boulevard

Lincolnshire, Illinois  60069

(847) 478-0500

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copy to:

Amy E. Culbert, Esq.

Oppenheimer Wolff & Donnelly LLP

222 South Ninth Street, Suite 2000

Minneapolis, Minnesota 55402

(612) 607-7287

 

 

Approximate date of commencement of proposed sale to the public:  Not applicable.  This post-effective amendment deregisters those securities that remain unissued or unsold hereunder as of the effective date hereof.

 

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  o

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or reinvestment plans, check the following box:  x

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

 

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  o

 

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o	Accelerated filer x	Non-accelerated filer o	Smaller reporting company o
		(Do not check if a smaller reporting company)

 

This Post-Effective Amendment to the Registration Statement on Form S-3 shall hereafter become effective in accordance with the provisions of Section 8(c) of the Securities Act of 1933, as amended.

 

 

 

DEREGISTRATION OF SECURITIES

 

On July 17, 2007, BioSante Pharmaceuticals, Inc. filed with the Securities and Exchange Commission a registration statement on Form S-3, as amended (Registration No. 333-144665), registering the resale of 3,818,749 shares of common stock, par value $0.0001 per share, by certain selling stockholders.  Pursuant to the undertaking contained in the registration statement, BioSante is filing this Post-Effective Amendment No. 1 to remove from registration all registered but unsold shares covered by the registration statement.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the registration statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lincolnshire, State of Illinois, on June 1, 2012.

 

	BIOSANTE PHARMACEUTICALS, INC.
	By	/s/ Stephen M. Simes
		Stephen M. Simes
		Vice Chairman, President and Chief Executive Officer
	By	/s/ Phillip B. Donenberg
		Phillip B. Donenberg
		Senior Vice President of Finance, Chief Financial
		Officer and Secretary

 

Pursuant to the requirements of the Securities Act of 1933, this amendment has been signed by the following persons in the capacities indicated, on the dates indicated.

 

Name and Signature			Title		Date
/s/ Stephen M. Simes			Vice Chairman, President and Chief Executive		June 1, 2012
Stephen M. Simes			Officer (Principal Executive Officer)
/s/ Phillip B. Donenberg			Senior Vice President of Finance, Chief		June 1, 2012
Phillip B. Donenberg			Financial Officer and Secretary
			(Principal Financial and Accounting Officer)
*			Chairman of the Board		June 1, 2012
Louis W. Sullivan, M.D.
*			Director		June 1, 2012
Fred Holubow
*			Director		June 1, 2012
Ross Mangano
/s/ John T. Potts, Jr., M.D.			Director		May 30, 2012
John T. Potts, Jr., M.D.
*			Director		June 1, 2012
Edward C. Rosenow, III, M.D.
/s/ Stephen A. Sherwin, M.D.			Director		May 30, 2012
Stephen A. Sherwin, M.D.
* By:	/s/ Stephen M. Simes		Attorney-in-Fact		June 1, 2012
	Stephen M. Simes

 

3